RxDoctor Payments DataLook up a doctor →

Adele Thiel, MD

Neurology · Flowood, MSNPI 1992810691

Payments from drug & device makers

$9,716in general payments, 2019–2025

Across 598 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • AbbVie$962
  • Sanofi$582
  • Acadia Pharmaceuticals Inc$539
  • Amgen$510
  • EMD Serono, Inc.$455
  • plus $6K from 39 others

What the payments were for

  • Speaking & faculty fees$2332%
  • Food & beverage$9,19795%
  • Education$2853%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,716 in reported general payments places this provider in the 65th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$157,440
Medicare patients
537
Services billed
8,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide15$211,808
AustedoDeutetrabenazine26$165,611
RebifInterferon Beta-1a/Albumin14$147,275
Austedo XrDeutetrabenazine13$95,830
UbrelvyUbrogepant36$51,216
Aimovig AutoinjectorErenumab-Aooe51$42,071
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$41,165
NamzaricMemantine Hcl/Donepezil Hcl43$32,099
Emgality PenGalcanezumab-Gnlm46$30,937
RytaryCarbidopa/Levodopa41$23,859
Keppra XrLevetiracetam23$19,710
Tegretol XrCarbamazepine18$12,564
Ajovy AutoinjectorFremanezumab-Vfrm16$11,210
Ajovy SyringeFremanezumab-Vfrm11$9,270
EliquisApixaban13$8,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,045$261,44039 claims
SanofiAubagio$582$211,80815 claims
EMD Serono, Inc.Rebif$455$147,27514 claims
AbbVieUbrelvy, Namzaric$962$83,31579 claims
CSL BehringPrivigen$35$41,16511 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$27$25,88770 claims
PfizerEliquis, Dilantin$162$13,57028 claims
Upsher-smith Laboratories LLCTopiramate$122$1,713103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 neurology providers in Mississippi.

Other neurology in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →